The paper trail appeared quietly on a summer afternoon: board resolutions, share allotment notices, the bureaucratic choreography of a financing round nearing its close. For Vivid Dx, an Oxford-based startup building what it calls a revolutionary sepsis diagnostic, the filings posted to UK Companies House suggest fresh capital is on the way—though how much, and from whom, remains unclear.
The documents, dated in mid-2026 filings, don't reveal dollar figures—those typically appear in the SH01 return of allotment, which hasn't posted yet. But the sequence—pre-emption rights waived, new articles of association approved—follows a familiar pattern for anyone who's watched British life-sciences companies raise money. Vivid Dx hasn't said anything publicly yet. The formal accounting that will spell out the round size and investor names hasn't landed. Neither has a press release.
Still, the timing tracks. At an LSI Europe event in December 2025, then-CEO John Sperzel mentioned plans to raise £3 million to push its rapid blood infection platform toward clinical validation. Whether the new round matches that target, or something else entirely, should become clear once the company files the final paperwork.
Building on Oxford Science Money
Since spinning out of the University of Oxford in 2022, Vivid Dx has received £3 million from Oxford Science Enterprises out of a £4 million commitment—the university's venture arm that backs research coming out of its labs. OSE committed the £4 million total back in early 2024, deploying it in tranches: £1.8 million that April, another £1.2 million in May of the following year, both rounds priced at £0.32 a share.
OSE now holds somewhere between a quarter and half of the company, according to publicly available shareholder disclosures, and seated a representative on Vivid's board when the first check cleared. The firm fits OSE's thesis—deep science, Oxford pedigree, a technology that could reshape clinical practice if it works.
Beyond venture capital, Vivid Dx has also tapped government grant programs. Three awards from Innovate UK, totaling £425,323 through mid-2026, have helped fund development milestones. The largest, a £325,323 Biomedical Catalyst grant, specifically supported work on automated microscopy—a piece of the broader diagnostic puzzle the company is assembling.
Raman Spectroscopy Meets Machine Learning
Here's the pitch: What if you could identify a bloodstream infection in thirty minutes, straight from the sample, no culture required?
Vivid Dx's platform uses single-cell Raman spectroscopy—essentially, shining laser light at bacterial cells and measuring how the light scatters—to generate unique metabolic fingerprints. Software trained on a growing database of spectral signatures then matches the pattern to a pathogen. For antimicrobial resistance testing, the system tracks deuterium oxide uptake, a metabolic marker that reveals whether a bug is susceptible or resistant to a given antibiotic. That process takes about three hours, still faster than conventional culture-based methods that can stretch to three days.
The founders—Oxford engineering professor Zhanfeng Cui, Raman specialist Wei Huang, and clinical collaborator Dr. Monique Andersson—built the company around technology developed in university labs. They operated under the name Ramanomics Limited until rebranding as Vivid Dx last year. The team, now somewhere between 11 and 50 employees if LinkedIn profiles are any guide, works out of Oxford Science Park.
In hospital microbiology labs, where sepsis cases arrive with little time to spare, diagnostic speed matters. A lot. Clinicians treating suspected bloodstream infections typically start patients on broad-spectrum antibiotics immediately, before any test results come back, because waiting 24 to 72 hours for a culture isn't really an option when mortality risk doubles with every hour of delay.
Existing rapid diagnostics—like T2 Biosystems' molecular panels that run directly from blood—deliver answers in three to five hours but only for specific pathogens they're designed to detect. Vivid Dx claims broader pathogen coverage with comparable or better turnaround times. Whether that holds up in larger clinical studies remains to be seen.
The Stakes Are High
The numbers around sepsis are grim. More than a third of U.S. hospital deaths involve sepsis, which kills at least 350,000 American adults each year, per CDC estimates. Globally, antimicrobial-resistant infections contributed to nearly 5 million deaths in 2019, with resistance directly causing 1.27 million of them, according to a major Lancet study.
Rapid diagnostics that enable targeted therapy—prescribing the right drug for the right bug, rather than carpet-bombing with broad-spectrum agents—could chip away at both problems: reducing mortality and slowing the evolutionary pressure that drives resistance in the first place.
Vivid Dx has been running its platform against real-world samples, testing more than 300 specimens from Oxford's Radcliffe Hospital. Preliminary data from those 300+ patient samples made an appearance at the ESCMID Global conference in Munich in 2026. At a December investor event in Europe, company leadership outlined plans to wrap clinical validation and pursue FDA Breakthrough Device designation, a regulatory pathway designed to speed approvals for technologies addressing unmet medical needs.
What's Next
The company's latest financing, assuming it closes as the filings suggest, will presumably fund that validation work and the early steps toward regulatory submissions. Vivid Dx operates in a crowded field—venture-backed diagnostics startups chasing sepsis have come and gone over the past decade, some flaming out spectacularly despite promising early data—but the technical approach is distinctive enough to have attracted both grant reviewers and institutional investors.
Details on the new round—co-investors, if any, and how the capital will be deployed—should emerge once the formal disclosures post and the company decides to talk about it. For now, the filings offer a glimpse, nothing more. But in the diagnostics world, where timelines stretch and capital burns fast, any fresh funding is worth noting.
